Progress in approved drugs from natural product resources

Abstract

Natural products (NPs) have consistently played a pivotal role in pharmaceutical research, exerting profound impacts on the treatment of human diseases. A significant proportion of approved molecular entity drugs are either directly derived from NPs or indirectly through modifications of NPs. This review presents an overview of NP drugs recently approved in China, the United States, and other countries, spanning various disease categories, including cancers, cardiovascular and cerebrovascular diseases, central nervous system disorders, and infectious diseases. The article provides a succinct introduction to the origin, activity, development process, approval details, and mechanism of action of these NP drugs.

Keywords

New drugs / Natural products / Structural modification

References

[1] Chopra B, Dhingra AK. Natural products: a lead for drug discovery and development[J]. Phytother Res, 2021, 35(9): 4660-4702.

[2] Sorokina M, Merseburger P, Rajan K, et al. COCONUT online: Collection of Open Natural Products Database[J]. J Cheminform, 2021, 13(1): 2.

[3] Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019[J]. J Nat Prod, 2020, 83(3): 770-803.

[4] U.S. Food and Drug Administration. New Drugs at FDA: CDER’s New M-olecular Entities and New Therapeutic Biological Products[EB/OL]. https://www.fda.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products.

[5] National Healthcare Security Administration. Edition of medicine list for national basic medical insurance, employment injury insurance and maternity insurance (2023). http://www.nhsa.gov.cn/art/2023/12/13/art_104_11673.html.

[6] U.S. Food and Drug Administration. Drug Approvals and Databases. https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases.

[7] Xiao Z, Hao Y, Liu B, et al. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China[J]. Leuk Lymphoma, 2002, 43(9): 1763-1768.

[8] Yang L, Li X, Huang W, et al. Pharmacological properties of indirubin and its derivatives[J]. Biomed Pharmacother, 2022, 151: 113112.

[9] Liu G, Song Y, Li C, et al. Arsenic compounds: the wide application and mechanisms applied in acute promyelocytic leukemia and carcinogenic toxicology[J]. Eur J Med Chem, 2021, 221: 113519.

[10] Griffin JD. Blood’s 70^th anniversary: arsenic-from poison pill to magic bullet[J]. Blood, 2016, 127(14): 1729-1730.

[11] Wang J, Wong YK, Liao F. What has traditional Chinese medicine delivered for modern medicine?[J]. Expert Rev Mol Med, 2018, 20: e4.

[12] Wang M, Li H, Liu W, et al. Dammarane-type leads panaxadiol and protopanaxadiol for drug discovery: biological activity and structural modification[J]. Eur J Med Chem, 2020, 189: 112087.

[13] Zhang H, Xu HL, Wang YC, et al. 20(S)-Protopanaxadiol-induced apoptosis in MCF-7 breast cancer cell line through the inhibition of PI3K/AKT/mTOR signaling pathway [J]. Int J Mol Sci, 2018, 19( 4): 1053.

[14] Huong NT, Son NT. Icaritin: a phytomolecule with enormous pharmacological values[J]. Phytochemistry, 2023, 213: 113772.

[15] Qin SK, Li Q, Ming Xu J, et al. Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival[J]. Cancer Sci, 2020, 111(11): 4218-4231.

[16] Bailly C. Molecular and cellular basis of the anticancer activity of the prenylated flavonoid icaritin in hepatocellular carcinoma[J]. Chem Biol Interact, 2020, 325: 109124.

[17] Lorence A, Nessler CL. Camptothecin, over four decades of surprising findings[J]. Phytochemistry, 2004, 65(20): 2735-2749.

[18] Gao C, Liang J, Zhu Y, et al. Menthol-modified casein nanoparticles loading 10-hydroxycamptothecin for glioma targeting therapy[J]. Acta Pharm Sin B, 2019, 9(4): 843-857.

[19] Khaiwa N, Maarouf NR, Darwish MH, et al. Camptothecin’s journey from discovery to WHO Essential Medicine: fifty years of promise[J]. Eur J Med Chem, 2021, 223: 113639.

[20] Wang X, Zhuang Y, Wang Y, et al. The recent developments of camptothecin and its derivatives as potential anticancer agents[J]. Eur J Med Chem, 2023, 260: 115710.

[21] Lü S, Wang J. Homoharringtonine and omacetaxine for myeloid hematological malignancies[J]. J Hematol Oncol, 2014, 7: 2.

[22] Zhang N. Summary of the approved natural small molecule antitumor compounds[J]. China Pharm, 2019, 22(9): 1702-1705.

[23] Harringtonine Injection[J]. Chin Tradit Herbal Drugs, 1978, (6): 23-24.

[24] Stewart JA, Krakoff IH. Homoharringtonine: a phase I evaluation[J]. Invest New Drugs, 1985, 3(3): 279-286.

[25] Gürel G, Blaha G, Moore PB, et al. U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome[J]. J Mol Biol, 2009, 389(1): 146-156.

[26] Lv J, Shi S, Zhang B, et al. Role of puerarin in pathological cardiac remodeling: a review[J]. Pharmacol Res, 2022, 178: 106152.

[27] Zhou YX, Zhang H, Peng C. Puerarin: a review of pharmacological effects[J]. Phytother Res, 2014, 28(7): 961-975.

[28] Xie RQ, Du J, Hao YM et al. Myocardial protection and mechanism of puerarin injection on patients of coronary heart disease with ischemia/reperfusion[J]. Chin J Integr Med, 2003, 23(12): 895-897.

[29] Guo R, Li L, Su J, et al. Pharmacological activity and mechanism of tanshinone IIA in related diseases[J]. Drug Des Devel Ther, 2020, 14: 4735-4748.

[30] Tian XH, Wu JH. Tanshinone derivatives: a patent review (January 2006-September 2012)[J]. Expert Opin Ther Pat, 2013, 23(1): 19-29.

[31] Ren J, Fu L, Nile SH, et al. Salvia miltiorrhiza in treating cardiovascular diseases: a review on its pharmacological and clinical applications[J]. Front Pharmacol, 2019, 10: 753.

[32] Li D, Rui YX, Guo SD, et al. Ferulic acid: a review of its pharmacology, pharmacokinetics and derivatives[J]. Life Sci, 2021, 284: 119921.

[33] Wang BH, Ou-Yang JP. Pharmacological actions of sodium ferulate in cardiovascular system[J]. Cardiovasc Drug Rev, 2005, 23(2): 161-172.

[34] Huang XP, Chen YC, Shan WE. Effect of sodium ferulate on the rheology of the blood in coronary artery disease in the elderly[J]. Pract Clin Med, 2005, 6(8): 32-35.

[35] Shen Z, Wu Y, Zhou L, et al. The efficacy of sodium ferulate combination therapy in coronary heart disease: a systematic review and meta-analysis[J]. Phytomedicine, 2023, 115: 154829.

[36] Chen H, He Y, Chen S, et al. Therapeutic targets of oxidative/nitrosative stress and neuroinflammation in ischemic stroke: applications for natural product efficacy with omics and systemic biology[J]. Pharmacol Res, 2020, 158: 104877.

[37] Shayani Rad M, Moohebati M, Mohajeri SA. Effect of celery (Apium graveolens) seed extract on hypertension: a randomized, triple-blind, placebo-controlled, cross-over, clinical trial[J]. Phytother Res, 2022, 36(7): 2889-2907.

[38] Ma X, Tan C, Zhu D, et al. Huperzine A from Huperzia species-an ethnopharmacolgical review[J]. J Ethnopharmacol, 2007, 113(1): 15-34.

[39] Xing SH, Zhu CX, Zhang R, et al. Huperzine A in the treatment of Alzheimer’s disease and vascular dementia: a meta-analysis[J]. Evid-Based Compl Alt, 2014, 2014: 363985.

[40] Zhu T, Wang L, Wang LP, et al. Therapeutic targets of neuroprotection and neurorestoration in ischemic stroke: applications for natural compounds from medicinal herbs[J]. Biomed Pharmacother, 2022, 148: 112719.

[41] Xiao G, Tang R, Yang N, et al. Review on pharmacological effects of gastrodin[J]. Arch Pharm Res, 2023, 46: 744-770.

[42] Naß J, Efferth T. Development of artemisinin resistance in malaria therapy[J]. Pharmacol Res, 2019, 146: 104275.

[43] Tu Y. Artemisinin-a gift from traditional Chinese medicine to the world (Nobel Lecture)[J]. Angew Chem Int Ed Engl, 2016, 55(35): 10210-10226.

[44] Ma N, Zhang Z, Liao F, et al. The birth of artemisinin[J]. Pharmacol Ther, 2020, 216: 107658.

[45] Brossi A, Venugopalan B, Dominguez Gerpe L, et al. Arteether, a new antimalarial drug: synthesis and antimalarial properties[J]. J Med Chem, 1988, 31(3): 645-650.

[46] Dondorp AM, Yeung S, White L, et al. Artemisinin resistance: current status and scenarios for containment[J]. Nat Rev Microbiol, 2010, 8(4): 272-280.

[47] Zeng B, Wei A, Zhou Q, et al. Andrographolide: a review of its pharmacology, pharmacokinetics, toxicity and clinical trials and pharmaceutical researches[J]. Phytother Res, 2022, 36(1): 336-364.

[48] Latif R, Wang CY. Andrographolide as a potent and promising antiviral agent[J]. Chin J Nat Med, 2020, 18(10): 760-769.

[49] Study on dehydrated andrographolide half succinate monopotassium salt and its injection[J]. Chin Tradit Herbal Drugs, 1978, (8): 1-6, 49.

[50] Kumar A, Ekavali, Chopra K, et al. Current knowledge and pharmacological profile of berberine: an update[J]. Eur J Pharmacol, 2015, 761: 288-297.

[51] Tian Y, Tang G, Gao Y, et al. Carrier-free small molecular self-assembly based on berberine and curcumin incorporated in submicron particles for improving antimicrobial activity[J]. ACS Appl Mater Interfaces, 2022, 14(8): 10055-10067.

[52] Imenshahidi M, Hosseinzadeh H. Berberine and barberry (Berberis vulgaris): a clinical review[J]. Phytother Res, 2019, 33(3): 504-523.

[53] Varma DR, Yue TL. Adrenoceptor blocking properties of atropine-like agents anisodamine and anisodine on brain and cardiovascular tissues of rats[J]. Br J Pharmacol, 1986, 87(3): 587-594.

[54] Zhang Y, Zou J, Wan F, et al. Update on the sources, pharmacokinetics, pharmacological action, and clinical application of anisodamine[J]. Biomed Pharmacother, 2023, 161: 114522.

[55] Lv JQ, Jiang Q, Guo TT. Effects of anisodamine hydrobromide on microcirculation and coronary endothelial function in patients undergoing cardiopulmonary resuscitation for cardiac arrest[J]. Chin J Emerg Resusc Disaster Med, 2022, 17(7): 856-859.

[56] Liu C, Shen FM, Le YY, et al. Antishock effect of anisodamine involves a novel pathway for activating alpha7 nicotinic acetylcholine receptor[J]. Crit Care Med, 2009, 37(2): 634-641.

[57] Xiu RJ, Hammerschmidt DE, Coppo PA, et al. Anisodamine inhibits thromboxane synthesis, granulocyte aggregation, and platelet aggregation. A possible mechanism for its efficacy in bacteremic shock[J]. JAMA, 1982, 247(10): 1458-1460.

[58] Eisenkraft A, Falk A. Possible role for anisodamine in organophosphate poisoning[J]. Br J Pharmacol, 2016, 173(11): 1719-1727.

[59] Zhu P, Li J, Fu X, et al. Schisandra fruits for the management of drug-induced liver injury in China: a review[J]. Phytomedicine, 2019, 59: 152760.

[60] Yu L, Wang F, Tai M, et al. 6H2L, a novel synthetic derivative of bifendate, induces apoptosis in hepatoma cells via mitochondrial and MAPK pathway[J]. Eur J Pharmacol, 2020, 882: 173299.

[61] Huang MH, Li H, Xue R, et al. Up-regulation of glycolipid transfer protein by bicyclol causes spontaneous restriction of hepatitis C virus replication[J]. Acta Pharm Sin B, 2019, 9(4): 769-781.

[62] Sun YK, Zhang YF, Xie L, et al. Progress in the treatment of drug-induced liver injury with natural products[J]. Pharmacol Res, 2022, 183: 106361.

[63] Cai Y, Ma W, Xiao Y, et al. High doses of baicalin induces kidney injury and fibrosis through regulating TGF-β/Smad signaling pathway[J]. Toxicol Appl Pharmacol, 2017, 333: 1-9.

[64] Yang JY, Li M, Zhang CL, et al. Pharmacological properties of baicalin on liver diseases: a narrative review[J]. Pharmacol Rep, 2021, 73(5): 1230-1239.

[65] Darwiche N, El-Banna S, Gali-Muhtasib H. Cell cycle modulatory and apoptotic effects of plant-derived anticancer drugs in clinical use or development[J]. Expert Opin Drug Discov, 2007, 2(3): 361-379.

[66] Weis TM, Perissinotti AJ, Nachar VR, et al. Dosing vincristine in dose-adjusted EPOCH-R: to cap or not to cap?[J]. J Clin Oncol, 2019, 37(31): 2952.

[67] Kaur R, Kaur G, Gill RK, et al. Recent developments in tubulin polymerization inhibitors: an overview[J]. Eur J Med Chem, 2014, 87: 89-124.

[68] Cech NB, Oberlies NH. From plant to cancer drug: lessons learned from the discovery of taxol[J]. Nat Prod Rep, 2023, 40(7): 1153-1157.

[69] Sofias AM, Dunne M, Storm G, et al. The battle of "nano" paclitaxel[J]. Adv Drug Deliv Rev, 2017, 122: 20-30.

[70] Atrafi F, et al. Intratumoral comparison of nanoparticle entrapped docetaxel (CPC634) with conventional docetaxel in patients with solid tumors[J]. Clin Cancer Res, 2020, 26(14): 3537-3545.

[71] Villanueva C, Bazan F, Kim S, et al. Cabazitaxel: a novel microtubule inhibitor[J]. Drugs, 2011, 71(10): 1251-1258.

[72] Mazieres J, Kowalski D, Luft A, et al. Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non-small-cell lung cancer[J]. J Clin Oncol, 2020, 38(3): 271-280.

[73] Motyka S, Jafernik K, Ekiert H, et al. Podophyllotoxin and its derivatives: potential anticancer agents of natural origin in cancer chemotherapy[J]. Biomed Pharmacother, 2023, 158: 114145.

[74] Shi RJ, Fan HY, Yu XH, et al. Advances of podophyllotoxin and its derivatives: patterns and mechanisms[J]. Biochem Pharmacol, 2022, 200: 115039.

[75] Zhao W, Cong Y, Li HM, et al. Challenges and potential for improving the druggability of podophyllotoxin-derived drugs in cancer chemotherapy[J]. Nat Prod Rep, 2021, 38(3): 470-488.

[76] Khaled M, Jiang ZZ, Zhang LY. Deoxypodophyllotoxin: a promising therapeutic agent from herbal medicine[J]. J Ethnopharmacol, 2013, 149(1): 24-34.

[77] Tobert JA, Bell GD, Birtwell J, et al. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers[J]. J Clin Invest, 1982, 69(4): 913-919.

[78] Havel RJ, Hunninghake DB, Illingworth DR, et al. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study[J]. Ann Intern Med, 1987, 107(5): 609-615.

[79] Robinson JG. Simvastatin: present and future perspectives[J]. Expert Opin Pharmacother, 2007, 8(13): 2159-2127.

[80] Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors[J]. Nat Rev Drug Discov, 2003, 2(7): 517-526.

[81] Dehnavi S, Sohrabi N, Sadeghi M, et al. Statins and autoimmunity: state-of-the-art[J]. Pharmacol Ther, 2020, 214: 107614.

[82] Kockx M, Jessup W, Kritharides L. Cyclosporin A and atherosclerosis-cellular pathways in atherogenesis[J]. Pharmacol Ther, 2010, 128(1): 106-118.

[83] Survase SA, Kagliwal LD, Annapure US, et al. Cyclosporin A-a review on fermentative production, downstream processing and pharmacological applications[J]. Biotechnol Adv, 2011, 29(4): 418-435.

[84] Geissler EK, Schlitt HJ. The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation[J]. Kidney Int, 2010, 78(11): 1075-1079.

[85] Zhang Y, Zhang J, Wang S. The role of rapamycin in healthspan extension via the delay of organ aging[J]. Ageing Res Rev, 2021, 70: 101376.

[86] Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation[J]. Clin Pharmacokinet, 2004, 43(10): 623-653.

[87] Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation[J]. Drugs, 2000, 59(2): 323-389.

[88] Harvey AL. The pharmacology of galanthamine and its analogues[J]. Pharmacol Ther, 1995, 68(1): 113-128.

[89] Heinrich M, Lee Teoh H. Galanthamine from snowdrop-the development of a modern drug against Alzheimer’s disease from local Caucasian knowledge[J]. J Ethnopharmacol, 2004, 92(2-3): 147-162.

[90] Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension[J]. Neurology, 2000, 54(12): 2261-2268.

[91] Li H, Liu Y, Tian D, et al. Overview of cannabidiol (CBD) and its analogues: atructures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer’s disease[J]. Eur J Med Chem, 2020, 192: 112163.

[92] Britch SC, Babalonis S, Walsh SL. Cannabidiol: pharmacology and therapeutic targets[J]. Psychopharmacology (Berl), 2021, 238(1): 9-28.

[93] Amsden GW. Erythromycin, clarithromycin, and azithromycin: are the differences real?[J]. Clin Ther, 1996, 18(1): 56-55.

[94] Zuckerman JM, Qamar F, Bono BR. Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline)[J]. Med Clin North Am, 2011, 95(4): 761-791.

[95] Markham A, Faulds D. Roxithromycin. an update of its antimicrobial activity, pharmacokinetic properties and therapeutic use[J]. Drugs, 1994, 48(2): 297-326.

[96] Van der Paardt AL, Akkerman OW, Gualano G, et al. Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis[J]. Eur Respir J, 2017, 49(3): 1601612.

[97] Kruger D, Prathapan P. Azithromycin: the first broad-spectrum therapeutic[J]. J Transl Autoimmun, 2020: 100062.

[98] Lonks JR, Goldmann DA. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections[J]. Clin Infect Dis, 2005, 40(11): 1657-1664.

[99] Dinos GP. The macrolide antibiotic renaissance[J]. Br J Pharmacol, 2017, 174(18): 2967-2983.

[100] Zhai BT, Sun J, Shi YJ, et al. Review targeted drug delivery systems for norcantharidin in cancer therapy[J]. J Nanobiotechnology, 2022, 20(1): 509.

[101] Epstein WL, Kligman AM. Treatment of warts with cantharidin[J]. AMA Arch Derm, 1958, 77(5): 508-511.

[102] Eichenfield LF, McFalda W, Brabec B, et al. Safety and efficacy of VP-102, a proprietary, drug-device combination product containing cantharidin, 0.7% (W/V), in children and adults with molluscum contagiosum: two phase 3 randomized clinical trials[J]. JAMA Dermatol, 2020, 156(12): 1315-1323.

[103] Křen V, Valentová K. Silybin and its congeners: from traditional medicine to molecular effects[J]. Nat Prod Rep, 2022, 39(6): 1264-1281.

[104] Abenavoli L, Capasso R, Milic N, et al. Milk thistle in liver diseases: past, present, future[J]. Phytother Res, 2010, 24(10): 1423-1432.

[105] Wadhwa K, Pahwa R, Kumar M, et al. Mechanistic insights into the pharmacological significance of silymarin[J]. Molecules, 2022, 27(16): 5327.

[106] Wesołowska O, Łania-Pietrzak B, Kuzdzał M, et al. Influence of silybin on biophysical properties of phospholipid bilayers[J]. Acta Pharmacol Sin, 2007, 28(2): 296-306.

[107] Li X, Sun R, Liu R. Natural products in licorice for the therapy of liver diseases: progress and future opportunities[J]. Pharmacol Res, 2019, 144: 210-226.

[108] Chen JX, Ding ZQ. Advances in natural product anti-coronavirus research (2002-2022)[J]. Chin Med, 2023, 18(1): 13.

[109] Li JY, Cao HY, Liu P, et al. Glycyrrhizic acid in the treatment of liver diseases: literature review[J]. Biomed Res Int, 2014, 2014: 872139.

[110] Bailey CJ, Day C. Metformin: its botanical background[J]. Pract Diab Int April, 2004, 21(3): 115-117.

[111] Slotta KH, Tschesche R. Über Biguanide, II. : Die blutzucker-senkende Wirkung der Biguanide[J]. Ber Dtsch Chem Ges, 1929, 62: 1398-1405.

[112] Bailey CJ. Metformin: historical overview[J]. Diabetologia, 2017, 60(9): 1566-1576.

[113] Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer[J]. Nat Rev Endocrinol, 2014, 10(3): 143-156.

[114] Ma T, Tian X, Zhang B, et al. Low-dose metformin targets the lysosomal AMPK pathway through PEN2[J]. Nature, 2022, 603(7899): 159-165.

[115] Dasgeb B, Kornreich D, McGuinn K, et al. Colchicine: an ancient drug with novel applications[J]. Br J Dermatol, 2018, 178(2): 350-356.

[116] Slobodnick A, Shah B, Krasnokutsky S, et al. Update on colchicine, 2017[J]. Rheumatology (Oxford), 2018, 57(suppl_1): i4-i11.

[117] Yang LP. Oral colchicine (Colcrys): in the treatment and prophylaxis of gout[J]. Drugs, 2010, 70(12): 1603-1613.

[118] Zhang FS, He QZ, Qin CH, et al. Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review[J]. Acta Pharmacol Sin, 2022, 43(9): 2173-2190.

[119] Trang T, Al-Hasani R, Salvemini D, et al. Pain and poppies: the good, the bad, and the ugly of opioid analgesics[J]. J Neurosci, 2015, 35(41): 13879-13888.

Funding

National Natural Science Foundation of China(32170406)